Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik